GlassScriptPhysician profile
Carlos G Micames
NPI 1598787491
$21,561.67
in general payments reported to CMS, 2019-2025
21 companies · $2,235 in 2025
The $2,235 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,449 · 2021: $2,049 · 2022: $453 · 2023: $9,667 · 2024: $2,710 · 2025: $2,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,750 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,100 · Food and Beverage: $3,734 · Education: $27.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,750.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,100.00 |
| Food and Beverage | $3,733.77 |
| Education | $27.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,217.12 | 2019-2025 | |
| Boston Scientific Corporation | $7,948.59 | 2019-2025 | Spyglass, General - Biliary Devices |
| E.R. Squibb & Sons, L.L.C. | $2,851.70 | 2019-2024 | Zeposia, Opdivo, Eliquis |
| Olympus Latin America, INC. | $446.86 | 2019-2025 | Evis Exera II Ultrasound Gastrovideoscope, Evis Exera III Colonovideoscope, Visiglide |
| Janssen Scientific Affairs, LLC | $290.68 | 2019-2021 | |
| Madrigal Pharmaceuticals | $253.90 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $213.36 | 2019-2025 | Livdelzi |
| Apollo Endosurgery US INC | $190.60 | 2021-2023 | Overstitch Endoscopic Suturing System |
| Janssen Pharmaceuticals, INC | $128.40 | 2023 | Stelara |
| Lilly USA, LLC | $125.00 | 2024 | Omvoh |
| Intercept Pharmaceuticals, INC. | $125.00 | 2019 | |
| Janssen Biotech, INC. | $117.34 | 2024 | Stelara, Tremfya |
| Steris Corporation | $101.44 | 2024 | |
| Merck Sharp & Dohme LLC | $98.04 | 2019 | |
| Allergan, INC. | $92.78 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer Pharmaceuticals LLC | $78.24 | 2019 | |
| Creo Medical INC. | $68.71 | 2024 | Speedboat Ultraslim (Sb1l) |
| Micro-Tech Endoscopy USA, INC. | $66.27 | 2023 | Eyemax |
| Pbg Puerto Rico LLC | $57.34 | 2021 | |
| Olympus America INC. | $55.37 | 2019 | |
| Organon LLC | $34.93 | 2022-2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Micames listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.